Epilepsy Research
Volume 91, Issue 1 , Pages 49-56 , September 2010

Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy

  • Linda Holtman

      Affiliations

    • Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Science Park 904, 1098 XH Amsterdam, The Netherlands
    • ,
  • Erwin A. van Vliet

      Affiliations

    • Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Science Park 904, 1098 XH Amsterdam, The Netherlands
    • Epilepsy Institute in The Netherlands Foundation (SEIN), Achterweg 5, 2103 SW Heemstede, The Netherlands
    • ,
  • Peter M. Edelbroek

      Affiliations

    • Epilepsy Institute in The Netherlands Foundation (SEIN), Achterweg 5, 2103 SW Heemstede, The Netherlands
    • ,
  • Eleonora Aronica

      Affiliations

    • Academic Medical Center, Department of (Neuro)Pathology, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    • ,
  • Jan A. Gorter

      Affiliations

    • Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Science Park 904, 1098 XH Amsterdam, The Netherlands
    • Epilepsy Institute in The Netherlands Foundation (SEIN), Achterweg 5, 2103 SW Heemstede, The Netherlands
    • Corresponding Author InformationCorresponding author at: Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Science Park 904, 1098 XH Amsterdam, The Netherlands. Tel.: +31 205257893; fax: +31 205257709.

Received 23 March 2010 ,Revised 2 June 2010 ,Accepted 23 June 2010.

References 

  1. Baik EJ, Kim EJ, Lee SH, Moon C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res. 1999;843:118–129
  2. Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol. Pharmacol. 2008;73:1444–1453
  3. Cavazos JE, Golarai G, Sutula TP. Septotemporal variation of the supragranular projection of the mossy fiber pathway in the dentate gyrus of normal and kindled rats. Hippocampus. 1992;2:363–372
  4. Gorter JA, van Vliet EA, Aronica E, Lopes da Silva FH. Progression of spontaneous seizures after status epilepticus is associated with mossy fibre sprouting and extensive bilateral loss of hilar parvalbumin and somatostatin-immunoreactive neurons. Eur. J. Neurosci. 2001;13:657–669
  5. Gorter JA, van Vliet EA, Aronica E, Breit T, Rauwerda H, Lopes da Silva FH, et al. Potential new anti-epileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J. Neurosci. 2006;26:11083–11110
  6. Govoni S, Masoero E, Favalli L, Rozza A, Scelsi R, Viappiani S, et al. The cycloxygenase-2 inhibitor SC58236 is neuroprotective in an in vivo model of focal ischemia in the rat. Neurosci. Lett. 2001;303:91–94
  7. Hewett SJ, Silakova JM, Hewett JA. Oral treatment with rofecoxib reduces hippocampal excitotoxic neurodegeneration. J. Pharmacol. Exp. Ther. 2006;319:1219–1224
  8. Holtman L, van Vliet EA, van Schaik R, Queiroz CM, Aronica E, Gorter JA. Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy. Epilepsy Res. 2009;84:56–66
  9. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, et al. Reduced susceptibility to ischemic brain injury and N-methyl-d-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 2001;98:1294–1299
  10. Jamali S, Bartolomei F, Robaglia-Schlupp A, Massacrier A, Peragut JC, Regis J, et al. Large-scale expression study of human mesial temporal lobe epilepsy: evidence for dysregulation of the neurotransmission and complement systems in the entorhinal cortex. Brain. 2006;129:625–641
  11. Jung KH, Chu K, Lee ST, Kim J, Sinn DI, Kim JM, et al. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol. Dis. 2006;23:237–246
  12. Kim HJ, Chung JI, Lee SH, Jung YS, Moon CH, Baik EJ. Involvement of endogenous prostaglandin F2alpha on kainic acid-induced seizure activity through FP receptor: the mechanism of proconvulsant effects of COX-2 inhibitors. Brain Res. 2008;1193:153–161
  13. Kunz T, Oliw EH. The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus. Eur. J. Neurosci. 2001;13:569–575
  14. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, San Diego. 1998;
  15. Pekcec A, Unkruer B, Schlichtiger J, Soerensen J, Hartz AM, Bauer B, et al. Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J. Pharmacol. Exp. Ther. 2009;330:939–947
  16. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972;32:281–294
  17. Ravizza T, Gagliardi B, Noe F, Boer K, Aronica E, Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol. Dis. 2008;29:142–160
  18. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 2004;56:387–437
  19. van Vliet EA. The Role of the Blood–Brain Barrier and Multidrug Transporters in Pharmacoresistant Epilepsy. Amsterdam: Center for Neuroscience, University of Amsterdam; 2007;
  20. van Vliet EA, Aronica E, Redeker S, Marchi N, Rizzi M, Vezzani A, et al. Selective and persistent upregulation of mdr1b mRNA and P-glycoprotein in the parahippocampal cortex of chronic epileptic rats. Epilepsy Res. 2004;60:203–213
  21. van Vliet EA, Aronica E, Tolner EA, Lopes da Silva FH, Gorter JA. Progression of temporal lobe epilepsy in the rat is associated with immunocytochemical changes in inhibitory interneurons in specific regions of the hippocampal formation. Exp. Neurol. 2004;187:367–379
  22. van Vliet EA, Van Schaik R, Edelbroek PM, Redeker S, Aronica E, Wadman WJ, et al. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia. 2006;47:672–680
  23. van Vliet EA, van Schaik R, Edelbroek PM, Lopes da Silva FH, Wadman WJ, Gorter JA. Development of tolerance to levetiracetam in rats with chronic epilepsy. Epilepsia. 2008;49:1151–1159
  24. van Vliet EA, Zibell G, Pekcec A, Schlichtiger J, Edelbroek PM, Holtman L, et al. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology. 2010;58:404–412
  25. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia. 2005;46:1724–1743
  26. Zibell G, Unkruer B, Pekcec A, Hartz AM, Bauer B, Miller DS, et al. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology. 2009;56:849–855

PII: S0920-1211(10)00158-0

doi: 10.1016/j.eplepsyres.2010.06.011

Epilepsy Research
Volume 91, Issue 1 , Pages 49-56 , September 2010

Article Tools

* Image Usage & Resolution